Project Grant R50CA305246
Award Date 9/1/26
Completion Date 8/30/31
Dollars Obligated $163K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- The National Cancer Institute awarded Mayo Clinic Jacksonville $127,983 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support mechanistically guided immunometabolic CAR-TIL therapy research for glioblastoma. The award funds development and evaluation of dual-engineered ME1-armored anti-PD-L1 CAR tumor-infiltrating lymphocytes in combination with intracranial administration of clemastine and bexarotene to address tumor heterogeneity and immune suppression in...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $620,671 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a bioresorbable implant for local delivery of chemotherapy to aggressive meningiomas. The project addresses treatment limitations in meningioma management. Meningiomas are the most common adult central nervous system tumors, with over 36,000 diagnosed annually in the United States. Current treatment—maximal safe surgical resection...
- The National Cancer Institute awarded Mayo Clinic $415,000 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to improve treatment sensitivity through SYK using novel translational models of uveal melanoma. Performance runs through April 30, 2028, at Mayo Clinic's Rochester, Minnesota facility. This is a project grant supporting development and evaluation of improved cancer treatment methods through laboratory and clinical research, including molecularly targeted...
- Federal Grant Award Summary Mayo Clinic Jacksonville received a $621,435 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2027. The award supports research and development of a novel alpha-emitting radiopharmaceutical therapy designed to treat radioiodine refractory differentiated thyroid cancer, a condition resistant to conventional radioactive iodine treatment....
- The National Cancer Institute awarded $498,582 to Mayo Clinic Jacksonville on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396, R01 Project Grant PA-25-301) to investigate acetylation as a post-translational mechanism that modulates T cell receptor signaling and enhances cancer immunotherapy efficacy. The research addresses suboptimal TCR signaling as a major immune resistance mechanism in cancer immunotherapy. The funded work establishes three primary aims: defining the role...
- The National Cancer Institute awarded Mayo Clinic $667,710 on March 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized Phase 2 trial evaluating blood-based tumor and immune markers for risk stratification and treatment response monitoring in oligometastatic castration-sensitive prostate cancer. The project integrates prostate cancer-derived extracellular vesicles and circulating tumor DNA as blood markers to identify patients who will benefit from...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $599,699 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop chimeric antigen receptor T-cell and tumor-infiltrating lymphocyte immunotherapies targeting glioblastoma. The research applies a "double-hit" strategy combining two adoptive T-cell therapies administered via Ommaya reservoir to bypass the...
- The National Institutes of Health National Cancer Institute awarded Mayo Clinic $659,028 on May 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate multi-modality treatment combinations for aggressive Ewing sarcoma with STAG2 loss. The research addresses radiation therapy–induced immunobiological changes in Ewing tumors, focusing on epigenetic reprogramming and immune system activation to enhance radiation response in STAG2-deficient tumors. The recipient's...
- The National Institutes of Health National Cancer Institute awarded $687,314 to Mayo Clinic Jacksonville on July 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate senescence and resistance mechanisms in glioblastoma and to develop combination therapeutic strategies that overcome drug resistance. The funded research examines how glioblastomas develop resistance to mitotic kinase and kinesin inhibitors (ispinesib, alisertib, volasertib, and etoposide) through...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...